Novel 3 .alpha.-amino steroids
    1.
    发明授权
    Novel 3 .alpha.-amino steroids 失效
    新型3α-氨基类固醇

    公开(公告)号:US4424218A

    公开(公告)日:1984-01-03

    申请号:US292791

    申请日:1981-08-14

    摘要: A 3-amino-steroid of the formula ##STR1## wherein W is selected from the group consisting of hydrogen and --OH and taken together with X is ethylidene, X is selected from the group consisting of ethyl, ##STR2## the wavy line indicates the substituent has the .alpha.- and .beta.-position, R.sub.1 is selected from the group consisting of hydrogen and --CH.sub.3, R.sub.2 is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms and hydroxyalkyl of 2 to 5 carbon atoms, R.sub.3 is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, hydroxyalkyl of 2 to 5 carbon atoms, acyl of organic acid of 2 to 8 carbon atoms, alkoxycarbonyl of 2 to 8 carbon atoms, acyl of an .alpha.-amino-carboxylic acid and a peptide of 2 to 3 .alpha.-amino-carboxylic acids and their non-toxic, pharmaceutically acceptable acid addition acids with the proviso that R.sub.2 and R.sub.3 are not both hydrogen and (i) when R.sub.1 is methyl, W and R.sub.2 are hydrogen and X is ##STR3## in the case R.sub.3 is not methyl, acetyl or derived from an anminocarboxylic acid, (ii) when R.sub.1 is --CH.sub.3, W is hydrogen, R.sub.2 is --CH.sub.3 and X is ##STR4## in the case R.sub.3 is not methyl or acetyl, (iii) when R.sub.1 is methyl, R.sub.2 and W are hydrogen, X is ##STR5## with the --OH having the (S) configuration and the amino group is in the .alpha.-position in the case R.sub.3 is not methyl (iiii) R.sub.2 and W are hydrogen, X is ##STR6## and the 3-amino is in the .alpha.-position in the case at least one of R.sub.1, R.sub.2 and R.sub.3 is not methyl and (iiiii) R.sub.2 and W are hydrogen, R.sub.1 is methyl, X is ##STR7## with the --OH having the (R) configuration and the 3-amino is in the .alpha.-position in the case R.sub.3 is not ethoxycarbonyl capable of stimulating the defenses of an organism, especially by potentializing the production of IgE (immunoglobulins E) and their preparation.

    摘要翻译: 其中W选自氢和-OH并与X一起并与X一起形成的式(I)的3-氨基类固醇是亚乙基,X选自乙烯基,波浪线 表示取代基具有α-和β-位,R 1选自氢和-CH 3,R 2选自氢,1至5个碳原子的烷基和2至5个碳原子的羟烷基 R 3选自氢,1至5个碳原子的烷基,2至5个碳原子的羟基烷基,2至8个碳原子的有机酸酰基,2至8个碳原子的烷氧基羰基, - 氨基 - 羧酸和2至3个α-氨基 - 羧酸的肽及其无毒的药学上可接受的酸加成酸,条件是R2和R3不同时为氢和(i)当R1为甲基时,W 在R 3不是甲基的情况下,R 2是氢并且X是,乙酰基或 (ii)当R 1为-CH 3时,W为氢,R 2为-CH 3,X为不是甲基或乙酰基的情况下为X,(ⅲ)当R 1为甲基时,R 2和W为 是氢,X是具有(S)构型的-OH,而在R3不是甲基的情况下氨基位于α位置(iiii),R2和W是氢,X是< IMAGE>和 在R1,R2和R3中的至少一个不是甲基的情况下,3-氨基是α-位,并且(iiiii)R 2和W是氢,R 1是甲基,X是OH,其中-OH具有 (R)构型,并且在R3不是能够刺激生物体的防御性的乙氧基羰基的情况下,特别是通过潜在地产生IgE(免疫球蛋白E)及其制备,3-氨基是α-位。

    Derivatives of 3-amino-pregn-5-ene
    2.
    发明授权
    Derivatives of 3-amino-pregn-5-ene 失效
    3-氨基妊娠-5-烯的衍生物

    公开(公告)号:US4444767A

    公开(公告)日:1984-04-24

    申请号:US436524

    申请日:1982-10-25

    CPC分类号: C07J41/00

    摘要: A compound selected from the group consisting of: 3-amino-.DELTA..sup.5 -pregnenes of the formula I: ##STR1## wherein X is selected from the group of ##STR2## the wavy lines indicate that the group may be in the .alpha.-or .beta.-position, R.sub.1 is selected from the group consisting of hydrogen and hydroxyalkyl or 2 to 5 carbon atoms, R.sub.2 is selected from the group consisting of hydrogen, hydroxyalkyl of 2 to 5 carbon atoms, acyl of an aliphatic carboxylic acid of 3 to 8 carbon atoms, alkoxycarbonyl of 2 to 8 carbon atoms, acyl of an .alpha.-amino-carboxylic acid or from a peptide of 2 to 3 amino acids of which amines may be either unsubstituted or mono-or disubstituted with alkyl of 1 to 5 carbon atoms with the proviso that R.sub.1 and R.sub.2 are not both hydrogen and that if the 3-amino group is in the .beta.-position, (i) when X is ##STR3## R.sub.1 and R.sub.2 are not both hydroxyethyl or (ii) when X is ##STR4## and R.sub.1 is hydrogen, R.sub.2 is not ethoxycarbonyl, the compound of the formula I wherein X is ##STR5## R.sub.1 is hydrogen and R.sub.2 is methyl, the 3-amino group is in the .alpha.-positionand their non-toxic, pharmaceutically acceptable acid addition salts which are useful as stimulants of the mammalian immune system.

    摘要翻译: 选自以下的化合物:式I的3-氨基-TATA 5-孕烯:其中X选自,波浪线表示该基团可以在 α-或β-位,R 1选自氢和羟基烷基或2至5个碳原子,R 2选自氢,2至5个碳原子的羟烷基,酰基的脂族羧酸的 2至8个碳原子的烷氧基羰基,2至8个碳原子的烷氧基羰基,α-氨基 - 羧酸的酰基或2至3个氨基酸的肽,其中胺可以是未取代的或被1至 5个碳原子,条件是R1和R2不同时为氢,如果3-氨基为β-位,则(i)当X为R 1和R 2不是羟乙基或(ii)当 X是,R 1是氢,R 2不是乙氧基羰基,其中X是R 1的式I化合物是h ydrogen和R2是甲基,3-氨基是α-位及其无毒的药学上可接受的酸加成盐,其可用作哺乳动物免疫系统的兴奋剂。

    Steroids
    3.
    发明授权
    Steroids 失效
    新型类固醇

    公开(公告)号:US4395408A

    公开(公告)日:1983-07-26

    申请号:US292794

    申请日:1981-08-14

    摘要: Novel 3-amino-steroids of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and methyl, W is selected from the group consisting of hydrogen and --OH and taken together with x forms ethylidene, X is selected from the group consisting of ethyl, ##STR2## and taken together with W forms ethylidene and the wavy lines signify that the substituents are in the .alpha. or .beta.-position with the proviso that when R.sub.1 is methyl and X is ethyl, ##STR3## W is --OH and their non-toxic, pharmaceutically acceptable acid addition salts and their preparation and intermediates therefore capable of stimulating immunitary activity.

    摘要翻译: 式(Ⅰ)的新型3-氨基类固醇,其中R 1选自氢和甲基,W选自氢和-OH,并与x一起形成亚乙基,X选自 由乙基组成的基团与W一起形成亚乙基,波浪线表示取代基在α或β-位,条件是当R 1是甲基且X是乙基时,W是 -OH及其无毒的药学上可接受的酸加成盐及其制备和中间体因此能够刺激免疫活性。

    Novel 11 beta-substituted-19-nor-steroids
    4.
    发明授权
    Novel 11 beta-substituted-19-nor-steroids 失效
    新型11型β-取代-19-去甲甾类

    公开(公告)号:US4634696A

    公开(公告)日:1987-01-06

    申请号:US760703

    申请日:1985-07-30

    摘要: Novel 19-nor-steroids of the formula ##STR1## wherein R.sub.1 is an organic group of 1 to 18 carbon atoms optionally containing at least one heteroatom with the atom immediately adjacent the 11-carbon atom being carbon, R.sub.2 is a hydrocarbon of 1 to 8 carbon atoms, X is the remainder of a pentagonal or hexagonal ring optionally substituted and optionally containing one unsaturated--bond, the A and B rings are selected from the group consisting of ##STR2## R' and R" are individually selected from the group consisting of hydrogen, --CN and alkyl of 1 to 4 carbon atoms with at least one being other than hydrogen, R.sub.x is selected from the group consisting of hydrogen and OR.sub.e, R.sub.e is selected from the group consisting of hydrogen, optionally substituted alkyl of 1 to 6 carbon atoms and acyl, R.sub.a may be in the E or Z positions as indicated by the wavy line and is selected from the group consisting of ##STR3## and acyloxy, R.sub.a ' and R.sub.a " are alkyl of 1 to 4 carbon atoms or taken together with the nitrogen atom form a heterocycle of 5 to 6 chain members optionally containing another heteroatom with the proviso that when A and B are ##STR4## R.sub.1 contains at least one nitrogen, phosphorus or silicium atom and when A and B are ##STR5## R.sub.1 is not a linear alkyl and their non-toxic, pharmaceutically acceptable acid addition salts having a remarkable antigluococorticoid activity, their preparation and novel intermediates.

    摘要翻译: 式(I)的新型19-去甲甾类化合物,其中R 1是任选地含有至少一个杂原子的碳原子数为1至18的有机基团,紧邻11个碳原子的原子是碳,R2是1的烃 至少8个碳原子,X是任选地被取代且任选地含有一个不饱和键的五边形或六边形环的剩余部分,A和B环选自由下列组成的组:(a) (c)< IMAGE>(d)和< IMAGE>(e)R'和R“分别选自氢,-CN和1至4个碳原子的烷基,其中至少一个是其它 R x选自氢和ORe,Re选自氢,任选取代的1至6个碳原子的烷基和酰基,R a可以在E或Z位置,如 波浪线,并且选自和酰氧基,Ra'和Ra“是烷基 1至4个碳原子或与氮原子一起形成任选含有另一个杂原子的5至6个链成员的杂环,条件是当A和B为至少一个氮,磷或硅原子时, A和B是,R1不是直链烷基及其无毒的药学上可接受的酸加成盐,具有显着的抗皮质激素活性,其制备和新型中间体。

    Novel 17 .alpha.-aryl-steroids
    5.
    发明授权
    Novel 17 .alpha.-aryl-steroids 失效
    新型17α-芳基类固醇

    公开(公告)号:US4203981A

    公开(公告)日:1980-05-20

    申请号:US692

    申请日:1979-01-03

    摘要: Novel steroids of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and acyl of an organic carboxylic acid of 1 to 18 carbon atoms, R.sub.2 is selected from the group consisting of optionally substituted aryl of 6 to 12 carbon atoms and optionally substituted heterocyclic selected from the group consisting of furyl, thienyl, pyridyl and pyrimidyl, the optional substituents being selected from the group consisting of hydroxy, alkyl and alkoxy of 1 to 4 carbon atoms, halogens and --CF.sub.3, the dotted line in the A ring indicates an optional .DELTA..sup.1(2) - double bond and A may be oxo and B is hydrogen or A is .DELTA.--OH and B is hydrogen or halogen or A and B form a .DELTA..sup.9(10) - double bond having very good anti-inflammatory activity and their preparation and novel intermediates.

    摘要翻译: 式(Ⅰ)的新型类固醇,其中R 1选自氢和1至18个碳原子的有机羧酸的酰基,R 2选自任选取代的6至12个碳原子的芳基 和任选取代的杂环基,其选自呋喃基,噻吩基,吡啶基和嘧啶基,任选的取代基选自羟基,1至4个碳原子的烷基和烷氧基,卤素和-CF 3, 环表示可选的DELTA 1(2) - 双键,A可以是氧代,B是氢或A是DELTA -OH,B是氢或卤素,或A和B形成具有非常特异的DELTA 9(10) - 双键 良好的抗炎活性及其制备及新型中间体。

    Novel 11.beta.-substituted -19-nor-steriods
    6.
    发明授权
    Novel 11.beta.-substituted -19-nor-steriods 失效
    新型11β-取代-19-去甲基异亮氨酸

    公开(公告)号:US5043332A

    公开(公告)日:1991-08-27

    申请号:US421526

    申请日:1989-10-13

    摘要: Novel 19-nor-steroids of the formula ##STR1## wherein R.sub.1 is an organic group of 1 to 18 carbon atoms optionally containing at least one heteroatom with the atom immediately adjacent the 11-carbon atom being carbon, R.sub.2 is a hydrocarbon of 1 to 8 carbon atoms, X is the remainder of a pentagonal or hexagonal ring optionally substituted and optionally containing one unsaturated--bond, the A and B rings are selected from the group consisting of ##STR2## R' and R" are individually selected from the group consisting of hydrogen, --CN and alkyl of 1 to 4 carbon atoms, R.sub.x is selected from the group consisting of hydrogen and OR.sub.e, R.sub.e is selected from the group consisting of hydrogen, optionally substituted alkyl of 1 to 6 carbon atoms and acyl, R.sub.a may be in the E or Z positions as indicated by the wavy line and is selected from the group consisting of ##STR3## and acyloxy, R'.sub.a and R".sub.a are alkyl of 1 to 4 carbon atoms or taken together with the nitrogen atom form a heterocycle of 5 to 6 chain members optionally containing another heteroatom--with the proviso that when A and B are ##STR4## wherein R' and R" are both hydrogen, R.sub.1 contains at least one nitrogen, phosphorus or silicium atom and when A and B are ##STR5## R.sub.1 is not a linear alkyl and their non-toxic, pharmaceutically acceptable acid addition salts having a remarkable antiglucocorticoid activity, their preparation and novel intermediates.

    摘要翻译: 式(I)的新型19-去甲甾类化合物,其中R 1是任选地含有至少一个杂原子的碳原子数为1至18的有机基团,紧邻11个碳原子的原子是碳,R2是1的烃 至少8个碳原子,X是任选地被取代且任选地含有一个不饱和键的五边形或六边形环的剩余部分,A和B环选自由下列组成的组:(a) (c)图像(d)图像(e)R'和R“分别选自氢,-CN和1至4个碳原子的烷基,R x选自 由氢和ORe组成,Re选自氢,任选取代的1至6个碳原子的烷基和酰基,Ra可以在如波形线所示的E或Z位置,并且选自 的< IMAGE>和酰氧基,R'a和R'a是1〜4个碳原子的烷基或与n 氢原子形成任选含有另一个杂原子的5至6个链成员的杂环,条件是当A和B为其中R'和R“均为氢时,R 1包含至少一个氮,磷或硅原子 当A和B是时,R1不是具有显着的抗糖皮质激素活性的直链烷基及其无毒的药学上可接受的酸加成盐,其制备和新的中间体。

    Novel 11.beta.-substituted-19-nor-steroids
    7.
    发明授权
    Novel 11.beta.-substituted-19-nor-steroids 失效
    新型11β-取代-19-去甲类固醇

    公开(公告)号:US4978657A

    公开(公告)日:1990-12-18

    申请号:US810316

    申请日:1985-12-17

    摘要: Novel 19-nor-steroids of the formula ##STR1## wherein R.sub.1 is an organic group of 1 to 18 carbon atoms optionally containing at leat one heteroatom with the atom immediately adjacent the 11-carbon atom being carbon, R.sub.2 is a hydrocarbon of 1 to 8 carbon atoms, X is the remainder of a pentagonal or hexagonal ring optionally substituted and optionally containing one unsaturated bond, the A and B rings are selected from the group consisting of ##STR2## R' and R" are individually selected from the group consisting of hydrogen, --CN and alkyl of 1 to 4 carbon atoms, R.sub.x is selected from the group consisting of hydrogen and OR.sub.e, R.sub.e is selected from the group consisting of hydrogen, optionally substituted alkyl of 1 to 6 carbon atoms and acyl, R.sub.a may be in the E or Z positions as indicated by the wavy line and is selected from the group consisting of ##STR3## and acyloxy, R.sub.a ' and R.sub.a " are alkyl of 1 to 4 carbon atoms or taken together with the nitrogen atom form a heterocycle of 5 to 6 chain members optionally containing another heteroatom with the proviso that when A and B are ##STR4## wherein R' and R" are both hydrogen, R.sub.1 contain at least one nitrogen, phosphorus or silicium atom and when A and B are ##STR5## R.sub.1 is not a linear alkyl and their non-toxic, pharmaceutically acceptable acid addition salts having a remarkable antiglucocorticoid activity, their preparation and novel intermediates.

    摘要翻译: 式(Ⅰ)的新型19-去甲甾类化合物,其中R 1是1至18个碳原子的有机基团,其任选地含有一个杂原子与紧邻11个碳原子的原子是碳,R 2是1的烃 至8个碳原子,X是任选地被取代且任选地含有一个不饱和键的五边形或六边形环的剩余部分,A和B环选自由下列组成的组: + TR R'和R“分别选自氢,-CN和1至4个碳原子的烷基,Rx选自氢和ORe,Re选自由以下组成的组: 氢,任选取代的1至6个碳原子的烷基和酰基,Ra可以在如波形线所示的E或Z位置,并且选自由下列组成的组:酰氧基,Ra'和Ra“是 具有1至4个碳原子的烷基或与氮原子一起形成 任选地含有另一个杂原子的5至6个链成员的杂环,条件是当A和B是R 1和B均为氢时,R 1包含至少一个氮,磷或硅原子,当A和 B是不具有显着的抗糖皮质激素活性的线性烷基及其无毒的药学上可接受的酸加成盐,其制备方法和新的中间体。

    Novel 11.beta.-substituted-19-nor-steroids
    8.
    发明授权
    Novel 11.beta.-substituted-19-nor-steroids 失效
    新型11β-取代-19-去甲类固醇

    公开(公告)号:US4547493A

    公开(公告)日:1985-10-15

    申请号:US501373

    申请日:1983-06-06

    摘要: Novel 19-nor-steroids of the formula ##STR1## wherein R.sub.1 is an organic group of 1 to 18 carbon atoms optionally containing at least one heteroatom with the atom immediately adjacent the 11-carbon atom being carbon, R.sub.2 is a hydrocarbon of 1 to 8 carbon atoms, X is the remainder of a pentagonal or hexagonal ring optionally substituted and optionally containing one unsaturated bond, the A and B rings are selected from the group consisting of ##STR2## R' and R" are individually selected from the group consisting of hydrogen, --CN and alkyl of 1 to 4 carbon atoms with at least one being other than hydrogen, R.sub.x is selected from the group consisting of hydrogen and OR.sub.e R.sub.e is selected from the group consisting of hydrogen, optionally substituted alkyl of 1 to 6 carbon atoms and acyl, R.sub.a may be in the E or Z positions as indicated by the wavy line and is selected from the group consisting of ##STR3## and acyloxy, R.sub.a ' and R.sub.a " are alkyl of 1 to 4 carbon atoms or taken together with the nitrogen atom form a heterocycle of 5 to 6 chain members optionally containing another heteroatom with the proviso that when A and B are ##STR4## R.sub.1 contains at least one nitrogen, phosphorus or silicium atom and when A and B are ##STR5## R.sub.1 is not a linear alkyl and their non-toxic, pharmaceutically acceptable acid addition salts having a remarkable antigluococorticoid activity, their preparation and novel intermediates.

    摘要翻译: 式(I)的新型19-去甲甾类化合物,其中R 1是任选地含有至少一个杂原子的碳原子数为1至18的有机基团,紧邻11个碳原子的原子是碳,R2是1的烃 至8个碳原子,X是任选地被取代且任选地含有一个不饱和键的五边形或六边形环的剩余部分,A和B环选自由下列组成的组:< IMAGE> + TR< IMAGE> R'和 R“分别选自氢,-CN和具有1至4个碳原子的烷基,其中至少一个不同于氢,Rx选自氢和ORe + L,Re选自 由氢,任选取代的1至6个碳原子的烷基和酰基组成的组Ra可以在如波形线所示的E或Z位置,并且选自由下列组成的组:酰基氧基,R a'和 R a“为1至4个碳原子的烷基或被取代 与氮原子一起形成任选含有另外杂原子的5至6个链成员的杂环,条件是当A和B为至少一个氮,磷或硅原子时,当A和B为 R1不是直链烷基及其无毒的药学上可接受的酸加成盐,具有显着的抗皮质激素活性,其制备和新型中间体。

    Novel 17-spirosultines
    9.
    发明授权
    Novel 17-spirosultines 失效
    小说17-spirosultines

    公开(公告)号:US4154730A

    公开(公告)日:1979-05-15

    申请号:US843962

    申请日:1977-10-20

    摘要: Novel 17-spirosultines of steroids and the corresponding .gamma.-hydroxy acids of the formula ##STR1## wherein R.sub.1 is alkyl of 1 to 4 carbon atoms, A is hydrogen and B is hydrogen or hydroxyl of .beta.configuration or A and B together form a double bond, X and Y together form the group ##STR2## or X is --OH and Y is ##STR3## and M is selected from the group consisting of hydrogen, --NH.sub.4 and an alkali metal having a remarkable progestomimetic and antialdosteronic activity and a novel process for their preparation and novel intermediates.

    摘要翻译: 类固醇的新型17-螺旋体和相应的式(I)的γ-羟基酸,其中R 1是1至4个碳原子的烷基,A是氢,B是氢或β构型的羟基或A和B一起形成 双键,X和Y一起形成基团,或X是-OH,Y是,M选自氢,-NH 4和具有显着的假动物模拟和反向递质活性的碱金属,和 新型制备方法及新型中间体。